AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

25 4 2022 07:01:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

25 4 2022 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

31 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Participate in Conferences During April 2022

29 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

10 3 2022 07:00:02 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology

03 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10

21 2 2022 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces retirement of chief financial officer and succession plan

10 1 2022 07:01:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces 2022 priorities

10 1 2022 07:00:02 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Present at Conferences During January 2022

05 1 2022 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

13 12 2021 07:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition

06 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director

15 11 2021 07:00:02 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells

10 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

08 11 2021 02:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition

04 11 2021 09:01:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress

03 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3

25 10 2021 07:00:00 提供 Nasdaq GlobeNewswire

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK

16 9 2021 07:00:01 提供 Nasdaq GlobeNewswire

Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors

15 9 2021 07:00:01 提供 Nasdaq GlobeNewswire